Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.

Investors can access a webcast via the Events page on Caribou’s website, where replays will remain available for at least 30 days.

News Market Reaction – CRBU

+5.36%

14 alerts

+5.36% Session close to close

+5.1% Peak in 20 hr 44 min

$181.00M Market Cap

0.8x Rel. Volume

In the Jun 29 session, CRBU gained 5.36%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with prior mild strength around conference appearances but contrasts with past selling on clinical updates. With modest short positioning, sustained gains could depend on follow-up data or financing developments rather than a squeeze.

Key Figures

Conference time: 10:00 a.m. ET Webcast availability: 30 days

2 metrics

Conference time 10:00 a.m. ET Start time of H.C. Wainwright 4th Annual Cell Therapy Virtual Conference fireside chat on June 30, 2026

Webcast availability 30 days Webcasts available on Caribou’s website for at least 30 days after the event

Historical Context

5 past events · Latest: Jun 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 11	Clinical data update	Positive	-7.3%	Reported strong ANTLER phase 1 vispa-cel efficacy and outlined ANTLER-3 trial.
Jun 11	Clinical data update	Positive	-7.3%	Presented longer follow-up CaMMouflage data for CB-011 with high response rates.
May 27	Conference participation	Neutral	+0.0%	Announced CEO fireside chat at 2026 Jefferies Global Healthcare Conference.
May 13	Conference participation	Neutral	+0.9%	Disclosed participation in H.C. Wainwright 4th Annual BioConnect Investor Conference.
May 12	Conference presentations	Positive	+0.0%	Planned EHA 2026 oral presentations for vispa-cel and CB-011 phase 1 trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical data updates have previously coincided with negative price reactions, while conference participation headlines have seen flat to mildly positive moves.

Key Terms

crispr, genome-editing, cell therapy, webcast

4 terms

crispr technical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

genome-editing technical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

Genome-editing is a set of laboratory techniques that make deliberate, targeted changes to an organism’s DNA—like using a word processor to correct, insert, or delete letters in a long instruction manual. For investors it matters because these tools enable new therapies, crops, and diagnostics that can create high-value products and markets, while also bringing technical risk, regulatory review, and ethical debate that influence development timelines, costs, and potential returns.

cell therapy medical

"H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

webcast technical

"For more information and a link to the webcast, visit the Events page"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com

FAQ

When will Caribou Biosciences (CRBU) present at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?

Caribou Biosciences will participate in a fireside chat on June 30, 2026, at 10:00 am ET. According to Caribou, the event is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

Who will represent Caribou Biosciences (CRBU) at the June 30, 2026 H.C. Wainwright cell therapy conference?

Caribou’s president and chief executive officer, Rachel Haurwitz, PhD, will participate in the fireside chat. According to Caribou, she will speak at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

How can investors access the Caribou Biosciences (CRBU) webcast for the H.C. Wainwright cell therapy conference?

Investors can access the webcast through the Events page on Caribou’s website. According to Caribou, the webcast link and additional event information will be available there for viewers.

How long will the Caribou Biosciences (CRBU) H.C. Wainwright conference webcast be available online?

The webcast will be available on Caribou’s website for at least 30 days after the event. According to Caribou, investors can view the replay during this post-event period.

Is the Caribou Biosciences (CRBU) appearance at the H.C. Wainwright 4th Annual Cell Therapy Conference virtual?

Yes, the event is part of a virtual conference hosted by H.C. Wainwright. According to Caribou, the fireside chat and webcast will be accessible online to interested investors.